Report cover image

Global PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Feb 08, 2025
Length 191 Pages
SKU # APRC19872972

Description

Summary

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

According to APO Research, The global PD-1 and PD-L1 Inhibitors market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for PD-1 and PD-L1 Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of PD-1 and PD-L1 Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-1 and PD-L1 Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitors sales, projected growth trends, production technology, application and end-user industry.


PD-1 and PD-L1 Inhibitors Segment by Company

Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors
PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors
Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1 and PD-L1 Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PD-1 and PD-L1 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global PD-1 and PD-L1 Inhibitors Market Size, 2020 VS 2024 VS 2031
1.3 Global PD-1 and PD-L1 Inhibitors Market Size Estimates and Forecasts (2020-2031)
1.4 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts (2020-2031)
1.5 Global PD-1 and PD-L1 Inhibitors Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global PD-1 and PD-L1 Inhibitors Market Dynamics
2.1 PD-1 and PD-L1 Inhibitors Industry Trends
2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 PD-1 and PD-L1 Inhibitors Market by Manufacturers
3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (2020-2025)
3.2 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (2020-2025)
3.3 Global PD-1 and PD-L1 Inhibitors Average Sales Price by Manufacturers (2020-2025)
3.4 Global PD-1 and PD-L1 Inhibitors Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application
3.7 Global PD-1 and PD-L1 Inhibitors Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
3.8.2 Global Top 5 and 10 PD-1 and PD-L1 Inhibitors Players Market Share by Revenue in 2024
3.8.3 2024 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3
4 PD-1 and PD-L1 Inhibitors Market by Type
4.1 PD-1 and PD-L1 Inhibitors Type Introduction
4.1.1 PD-1 Inhibitors
4.1.2 PD-L1 Inhibitors
4.2 Global PD-1 and PD-L1 Inhibitors Sales by Type
4.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Type (2020-2031)
4.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2020-2031)
4.3 Global PD-1 and PD-L1 Inhibitors Revenue by Type
4.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2020-2031)
4.3.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2020-2031)
5 PD-1 and PD-L1 Inhibitors Market by Application
5.1 PD-1 and PD-L1 Inhibitors Application Introduction
5.1.1 Solid Tumors
5.1.2 Blood-related Tumors
5.2 Global PD-1 and PD-L1 Inhibitors Sales by Application
5.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Application (2020-2031)
5.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2020-2031)
5.3 Global PD-1 and PD-L1 Inhibitors Revenue by Application
5.3.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2020-2031)
5.3.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2020-2031)
6 Global PD-1 and PD-L1 Inhibitors Sales by Region
6.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2020 VS 2024 VS 2031
6.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2020-2031)
6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Region (2020-2025)
6.2.2 Global PD-1 and PD-L1 Inhibitors Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global PD-1 and PD-L1 Inhibitors Revenue by Region
7.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region
7.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2020-2025)
7.1.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2026-2031)
7.1.4 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America PD-1 and PD-L1 Inhibitors Revenue (2020-2031)
7.2.2 North America PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe PD-1 and PD-L1 Inhibitors Revenue (2020-2031)
7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue (2020-2031)
7.4.2 Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue (2020-2031)
7.5.2 South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Merck
8.1.1 Merck Comapny Information
8.1.2 Merck Business Overview
8.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
8.1.5 Merck Recent Developments
8.2 Bristol-Myers Squibb
8.2.1 Bristol-Myers Squibb Comapny Information
8.2.2 Bristol-Myers Squibb Business Overview
8.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
8.2.5 Bristol-Myers Squibb Recent Developments
8.3 Roche
8.3.1 Roche Comapny Information
8.3.2 Roche Business Overview
8.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
8.3.5 Roche Recent Developments
8.4 AstraZeneca
8.4.1 AstraZeneca Comapny Information
8.4.2 AstraZeneca Business Overview
8.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
8.4.5 AstraZeneca Recent Developments
8.5 Ono Pharmaceutical
8.5.1 Ono Pharmaceutical Comapny Information
8.5.2 Ono Pharmaceutical Business Overview
8.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
8.5.5 Ono Pharmaceutical Recent Developments
8.6 Regeneron
8.6.1 Regeneron Comapny Information
8.6.2 Regeneron Business Overview
8.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
8.6.5 Regeneron Recent Developments
8.7 Innovent
8.7.1 Innovent Comapny Information
8.7.2 Innovent Business Overview
8.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
8.7.5 Innovent Recent Developments
8.8 Hengrui Medicine
8.8.1 Hengrui Medicine Comapny Information
8.8.2 Hengrui Medicine Business Overview
8.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
8.8.5 Hengrui Medicine Recent Developments
8.9 Junshi Biosciences
8.9.1 Junshi Biosciences Comapny Information
8.9.2 Junshi Biosciences Business Overview
8.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
8.9.5 Junshi Biosciences Recent Developments
8.10 Merck KGaA
8.10.1 Merck KGaA Comapny Information
8.10.2 Merck KGaA Business Overview
8.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
8.10.5 Merck KGaA Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
9.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 PD-1 and PD-L1 Inhibitors Production Mode & Process
9.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 PD-1 and PD-L1 Inhibitors Distributors
9.2.3 PD-1 and PD-L1 Inhibitors Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us